Eris Lifesciences Ltd. (ERIS) fundamentals
Eris Lifesciences Ltd. is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as ERIS (ISIN INE406M01024). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Eris Lifesciences Ltd. does
Eris Lifesciences Limited is an India-based pharmaceutical company. The Company is engaged in the manufacture and marketing of pharmaceutical products. The Company has a presence in major therapies like oral anti-diabetes, insulins, cardiovascular, vitamins/minerals and dermatology. Its flagship therapies include oral anti-diabetes, cardiovascular disease (CVD), and vitamins, minerals and nutrients (VMN). Its emerging therapies consist of dermatology, insulins, women’s health, central nervous system (CNS), oncology, and nephrology. Its portfolio of brands includes Glimisave, Eritel, LNBloc, Olmin, Crevast, Atorsave, Gluxit, Renerve, Zomelis, Cosvate, Tayo, Cyblex, Remylin, Tendia, Rabonik, Ginkocer, Psorid, Raricap, Serlift, and Onabet, among others. Its patient care initiatives (PCI) platform provides various healthcare solutions to its patients. The Company has a manufacturing plant located in Guwahati, Assam.
Valuation and market data
| Last close | ₹1358.00 |
|---|---|
| Market capitalisation | ₹19,683 crore |
| Enterprise value | ₹22,008 crore |
| P/E (TTM) | 0.00 |
| Price to book | 6.02 |
| Price to sales (TTM) | 6.08 |
| Book value per share | ₹225.73 |
| Dividend yield | 53.09% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Thu Jun 29 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹1,920 crore | ₹362 crore | ₹244 crore | 0.00 |
| Mar 2025 | ₹1,733 crore | ₹120 crore | ₹77 crore | 5.69 |
| Mar 2024 | ₹1,522 crore | ₹329 crore | ₹300 crore | 22.04 |
| Mar 2023 | ₹1,348 crore | ₹437 crore | ₹398 crore | 29.27 |
| Mar 2022 | ₹1,245 crore | ₹459 crore | ₹417 crore | 30.70 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 54.1% |
|---|---|
| Foreign institutions (FII) | 5.8% |
| Mutual funds | 18.9% |
| Other domestic institutions | 1.8% |
| Retail and others | 19.4% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.